Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
Details : Leuprolide Acetate is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Batoclimab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HanAll’s Batoclimab gets Japan Orphan Drug Status for Thyroid Eye Disease
Details : IMVT-1401 (batoclimab) is an anti-FcRn antibody candidate, which is being evaluated for the treatment of active thyroid eye disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Batoclimab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HL192
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : NurrOn Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
HanAll, Daewoong and NurrOn Complete First Human Parkinson’s Therapy Study
Details : HL192(ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, it is being investigating for treating Parkinson's Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : HL192
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : NurrOn Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery Platform
Sponsor : Turn Biotechnologies
Deal Size : $300.0 million
Deal Type : Licensing Agreement
HanAll Signs Licensing Agreement with Turn Biotechnologies for Eye and Ear Treatments
Details : The collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery Platform
Sponsor : Turn Biotechnologies
Deal Size : $300.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease
Details : Tanfanercept is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 06, 2024
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HanAll Biopharma Begins Phase 3 VELOS-4 Trial for Tanfanercept in Dry Eye Disease
Details : HK036 (tanfanercept) is a potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor (TNF). It is being evaluated for the treatment of dry eye disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 03, 2024
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATH-399A
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : NurrOn Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
Details : ATH-399A is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2023
Lead Product(s) : ATH-399A
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : NurrOn Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HL192
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HL192 (ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, a master regulator associated with the development and maintenance of dopaminergic neurons, for the potential treatment of Parkinson's Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2023
Lead Product(s) : HL192
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Recipient : Vincere Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to develop small-molecule, first-in-class disease-modifying therapies by targeting the modulation of mitochondrial quality control mechanisms such as mitophagy for Parkinson's patients by leveraging Vincere's proprietary AI platfor...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : Vincere Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ATH-399A
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : NurrOn Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative dis...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 25, 2023
Lead Product(s) : ATH-399A
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : NurrOn Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement